Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Tiziana Life Sciences LtdNASDAQ: TLSA

Operating Expenses · Q4 FY2025 · quarter ended Dec 2025

Operating expenses grows 33.4% year over year

Q4 FY2025 operating expenses of $12.18M rose 33.4% year over year. Over 3 fiscal years it compounded at +5.5% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$12.18M— QoQ
Last fiscal yearDec 2025
$21.05M+33.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.4%——
1 year+33.3%——
3-year CAGR+5.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
21.05M USD
Year-over-year change
+33.3%
4-year CAGR
-13.1%

Operating Expenses vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 operating expenses of $21.05M is the 7th highest of the 9 companies compared; the peer median is $77.23M.
  • Its year-over-year change of +33.3% is the 5th highest of 9, against a peer median of +21.6%.
  • Over three fiscal years its annual growth of +5.5% compares with a peer median of +22.5%.
TLSA Competitors Peer median
Operating Expenses for TLSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M -10.6%-12.1%110.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$144.89M -39.4%-12.4%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$122.7M +143.6%+40.1%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$118.5M -49.4%+2.7%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$35.95M +65.2%+48.4%—
COYACoya Therapeutics, Inc.LTM Mar 2026$29.92M +225.6%+73.5%376.8%
TLSATiziana Life Sciences LtdFY2025$21.05M +33.3%+5.5%—
EXOZeXoZymes, Inc.LTM Mar 2026$10.15M +53.8%+101.7%—
OKYOOKYO Pharma LimitedFY2025$7.19M -54.2%+4.9%—
Peer median (excluding TLSA) $77.23M+21.6%+22.5%243.6%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000234K
Gross Profit0000(234K)
Gross Margin—————
Research & Development17.82M15.92M10.25M5.23M10.28M
Selling, General & Admin1.15M4.76M8.26M10.28M10.77M
Operating Expenses36.93M17.93M22.73M15.79M21.05M
Depreciation & Amortization190.2K62.68K121.34K124K234K
EBITDA(35.53M)(18.85M)(21.66M)(16.62M)(21.05M)
EBITDA Margin—————
Operating Income(36.93M)(17.93M)(22.73M)(15.79M)(21.28M)
Operating Margin—————
Interest Income001.46M814K19K
Interest Expense237.41K8.6K12.64K6K18K
Other Income / Expenses967.18K(996.78K)937.89K(952K)2.85M
Income Before Tax(35.96M)(18.92M)(21.79M)(16.75M)(18.43M)
Pre-Tax Margin—————
Income Tax Expense(4.37M)0567.54K(4.88M)0
Net Income(31.59M)(18.92M)(22.36M)(11.86M)(18.43M)
Net Margin—————
EPS (Basic)(0.64)(0.36)(0.42)(0.22)(0.32)
EPS (Diluted)(0.64)(0.36)(0.42)(0.22)(0.32)
Weighted Avg Shares48.97M50.76M50.76M53.34M59.14M
Weighted Avg Shares (Diluted)48.97M50.76M50.76M53.34M59.14M

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.